Phase III Clinical Study of JTE-052 Ointment - Long-Term Study of JTE-052 Ointment in Japanese infant Patients with Atopic Dermatitis -

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225316

Enrollment

Registered

2020-08-17

Start date

2020-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

investigational material(s) Generic name etc : JTE-052 INN of investigational material : delgocitinib Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with mild, moderate or severe atopic dermatitis

Exclusion criteria

Exclusion criteria: Active infection at the prospective application site History of tuberculosis Hepatitis B/C virus carriers or history of hepatitis B/C virus infection History or presence of malignant tumor

Design outcomes

Primary

Measure	Time frame
safety Adverse event	—

Secondary

Measure	Time frame
efficacy modified Eczema Area and Severity Index Investigator's Global Assessment Pruritus score	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026